Multiple Sclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Microglia-mediated neuroinflammation accompanies many central nervous system (CNS) diseases, including multiple sclerosis (MS), and is strongly dependent on the purinergic P2X7 receptor.
|
30209761 |
2019 |
Multiple Sclerosis
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
In the neuroinflammatory foci of MS there is increased expression of a purinergic receptor, P2X7R.
|
30908981 |
2019 |
Multiple Sclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
In this review, we will summarize recent findings highlighting the potential of P2X4 and P2X7 as therapeutic targets for MS.
|
31015145 |
2019 |
Multiple Sclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Purinergic receptor P2Y<sub>12</sub> (P2Y<sub>12</sub> ), a G protein-coupled purinergic receptor, is widely distributed in nervous system and involved in the progression of neurological diseases such as multiple sclerosis and neuropathic pain.
|
29341465 |
2019 |
Multiple Sclerosis
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
In particular, ionotropic purinergic receptors P2X4 and P2X7 and metabotropic receptor P2Y12 are differently expressed along the disease and their activation or blockage modifies the course of texperimental autoimmune encephalomyelitis (EAE), the dominant animal model of MS.
|
30500565 |
2019 |
Multiple Sclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Recently, numerous evidences further suggested the significance of P2X7R in the pathogenesis of autoimmune diseases, including systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), inflammatory bowel disease (IBD), multiple sclerosis (MS), etc.
|
31181327 |
2019 |
Multiple Sclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Our study nominates rare genetic variants in P2RX4 and P2RX7 as major genetic contributors to disease, further supporting a role for these purinergic receptors in MS and the disruption of transmembrane cation channels leading to impairment of phagocytosis as the pathological mechanisms of disease.
|
28326637 |
2017 |
Multiple Sclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Our results suggest that inhibition of P2X7R on monocytes and up-regulation in astrocytes might contribute to sustain inflammatory mechanisms in MS. By acquiring further knowledge about P2X7R dynamics and identifying P2X7R as a potential marker for the disease, we expect to gain insights into the molecular pathways of MS.
|
29187851 |
2017 |
Multiple Sclerosis
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
In the current study, we further characterized its binding profile and determined whether [C]GSK1482160 can detect changes in P2X7R expression in a rodent model of multiple sclerosis.
|
28338530 |
2017 |
Multiple Sclerosis
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Analysis shows Arg307Gln always occurred with 270His suggesting a single 307Gln-270His haplotype that confers dominant negative effects on P2X7 function and protection against MS.
|
26188005 |
2015 |
Multiple Sclerosis
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Here, we have explored the putative association of functionally relevant single nucleotide polymorphisms of the P2X7 receptor gene with multiple sclerosis.
|
21906809 |
2011 |
Multiple Sclerosis
|
0.400 |
Biomarker
|
disease |
CTD_human |
P2X(7) receptor blockade prevents ATP excitotoxicity in oligodendrocytes and ameliorates experimental autoimmune encephalomyelitis.
|
17728465 |
2007 |